Developer docs
API playgroundTry for free, no card

Search company profiles

Bora Biologics

Full company profile

uuid003yaan

Namestring
Bora Biologics
Legal namestring
Bora Biologics BioPharma, Inc.
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Bora Biologics is a San Diego-headquartered contract development and manufacturing organization (CDMO) specializing in mammalian and microbial biologics, founded in 2011 as a subsidiary of Taiwan-based Tanvex BioPharma, Inc. The company provides end-to-end services spanning cell line development, upstream and downstream process development, analytical development, formulation development, GMP drug substance manufacturing, and tech transfer, with drug product fill-finish delivered through affiliate Bora Pharmaceuticals' 87,000 sf facility in Baltimore, MD. Its proprietary technology stack includes a CHO cell line platform achieving 4-6 g/L titers, an Allosteric Formulation Development Platform, and a Biophysical High Throughput Platform that uses advanced spectroscopic and biophysical instrumentation for rapid formulation screening. The company operates an FDA-registered facility in San Diego with newly validated 2,000L single-use bioreactor capacity (following a $30M expansion completed January 2026) and a TFDA-registered cGMP facility in Zhubei City, Taiwan, together totaling more than 175,000 sf of GMP and R&D space.

Bora Biologics employs 125 scientists and regulatory specialists (over 50% with advanced degrees) and has delivered 100+ cGMP batches across 50 biologic and biosimilar programs, including one commercial biosimilar approved in both the U.S. and Canada. Revenue is generated through project-based, fee-for-service CDMO contracts priced per engagement scope, typically structured as multi-year agreements with enterprise biopharma sponsors. The go-to-market model relies on direct enterprise sales, technical publications, case studies, and conference participation (BIO 2026, CDMO Live Europe), targeting mid-to-large biopharma and biotech sponsors needing late-stage and commercial-scale biologics manufacturing, particularly those seeking U.S.-based supply. Recent strategic activity — including the May 2026 acquisition of MacroGenics' GMP operations and the commercial-scale 2,000L validation — positions Bora as a scaling mid-market biologics CDMO with both clinical and commercial manufacturing capability across two regulatory jurisdictions.

Short descriptiontext

Bora Biologics is a San Diego-based contract development and manufacturing organization (CDMO) specializing in mammalian and microbial biologics from cell line development through commercial GMP manufacturing and fill-finish services for biopharma sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract biologics manufacturing, mammalian cell culture, microbial fermentation, biologics process development, fill-finish services
Industry2 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biologics Contract Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing (CDMO) Services
TypeProfessional Services
Description

Bora Biologics generates revenue through providing fee-for-service contract development and manufacturing services to biopharma sponsors. Services span the full product lifecycle from cell line development, process development, analytical development, GMP manufacturing (drug substance), through technology transfer. Revenue is project-based with custom scopes, timelines, and pricing negotiated per engagement. The company also transfers drug substances to its affiliate Bora Pharmaceuticals for fill-finish and drug product services, forming an integrated end-to-end CDMO offering.

borabiologics.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1Custom CDMO project pricing — scope-dependent, quote-based
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing tiers. Each engagement is scoped individually based on service line (development, manufacturing, tech transfer), molecule type, batch scale, and regulatory requirements.

borabiologics.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Bora Biologics is a contract development and manufacturing organization (CDMO) that provides end-to-end biologics services spanning cell line development, mammalian and microbial process development, analytical and formulation development, GMP drug substance manufacturing, and fill-finish drug product services. The company operates FDA-registered facilities in San Diego, CA and TFDA-registered facilities in Zhubei City, Taiwan, serving biopharma sponsors from preclinical through commercial-scale production of monoclonal antibodies, bispecifics, ADCs, fusion proteins, enzymes, and biosimilars.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 40% increase in mammalian process yield through process development optimization
+4 more records
Product overview1 text field

Bora Biologics is a technology-driven Contract Development and Manufacturing Organization (CDMO) offering an integrated platform spanning development through commercialization. The core offering consists of Mammalian GMP Manufacturing and Microbial GMP Manufacturing, complemented by development service modules including Cell Line Development, Mammalian Process Development, Microbial Process Development, Analytical Development, Formulation & Drug Product Development, and Tech Transfer. Drug Product Services (fill-finish) are delivered through partnership with Bora Pharmaceuticals. The company specializes in late-stage execution and commercial-scale production of biologics including monoclonal antibodies, bispecifics, ADCs, fusion proteins, and enzymes at FDA-registered facilities in San Diego, CA and Zhubei City, Taiwan.

Product and service9 records
1Mammalian GMP Manufacturing
CategoryManufacturing
Description

Full-service mammalian cell culture manufacturing using single-use bioreactor technology (50L to 2,000L scale) with integrated upstream, downstream, and quality systems at the FDA-registered San Diego facility. Designed for biopharma sponsors requiring clinical-to-commercial scale GMP production.

2Microbial GMP Manufacturing
CategoryManufacturing
Description

Efficient microbial-derived biologics manufacturing using stainless steel fermentors (150L, 300L) and single-use fermentation technology for secreted and intracellular products, serving sponsors from pre-clinical through commercial scale.

3Drug Product Services
CategoryManufacturing
Description

Comprehensive fill-finish services including vials and pre-filled syringes, liquid and lyophilization, visual inspection, packaging, and serialization. Delivered through partnership with affiliate Bora Pharmaceuticals at the Baltimore, MD facility for clinical and commercial drug product manufacturing.

4Cell Line Development
CategoryDevelopment
Description

Robust cell line development using a proprietary CHO cell line platform with CRISPR/Cas9 gene editing, clone screening, and characterization to create high-yield, stable cell lines for biologics production.

5Mammalian Process Development
CategoryDevelopment
Description

Optimization of cell culture and downstream purification processes including high-throughput media screening, chromatography development, filtration process development, and scale-up to 2,000L batches for mammalian biologics production.

6Microbial Process Development
CategoryDevelopment
Description

Scalable fermentation development for E. coli and yeast systems, including high-yield fermentation optimization, downstream purification, and process scale-up from pre-clinical to commercial scale.

7Analytical Development
CategoryDevelopment
Description

Comprehensive analytical services including identity and purity testing, structural characterization, biological/functional characterization, microbiology testing, and analytical method validation for biologics.

8Formulation & Drug Product Development
CategoryDevelopment
Description

Drug product formulation development using a proprietary Allosteric Formulation Development Platform and Biophysical HT Platform for rapid pre-formulation screening, stability assessment, and excipient compatibility studies.

9Tech Transfer
CategoryDevelopment
Description

Technology transfer services ensuring smooth transition from development to manufacturing, including comprehensive assessment, cross-functional collaboration, and robust documentation practices; particularly used to transition Asia-based programs to U.S. commercial supply.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bora Biologics transfers biologic drug substances to its affiliate Bora Pharmaceuticals for comprehensive drug product (fill-finish) services. Bora Pharmaceuticals operates an 87,000 sf cGMP drug product facility in Baltimore, MD. This partnership enables an end-to-end CDMO offering from drug substance to drug product under an integrated 'Power of One' single-agreement model. The collaboration provides clinical and commercial manufacturing capabilities for vials, pre-filled syringes, liquid and lyophilized products, with inspection, packaging, and serialization.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Through its pharma services segment, Thermo Fisher offers biologics CDMO capabilities including mammalian manufacturing and fill-finish. Competes with Bora across most service lines, with the advantage of integrated small-molecule, biologics, and clinical-trial-services capabilities.

TypeBroad incumbent
Description

Global CDMO leader offering mammalian and microbial biologics development and manufacturing across multiple sites in Switzerland, the U.S., and Asia. Competes directly with Bora across the full biologics CDMO value chain, with far larger scale and longer commercial track record.

TypeBroad incumbent
Description

One of the world's largest biologics CDMOs with 364,000L of total bioreactor capacity across multiple plants in Songdo, South Korea. Directly competes with Bora for late-stage and commercial mammalian biologics manufacturing, but at substantially larger scale and with broader capabilities.

TypeBroad incumbent
Description

Major China-based biologics CDMO with extensive global capacity and integrated discovery-through-commercial services. Competes head-to-head with Bora for mammalian biologics programs, particularly sponsors with Asia-based clinical development seeking a CDMO partner.

TypeDirect peer
Description

Mid-to-large global CDMO offering mammalian and microbial biologics development and manufacturing from clinical through commercial scale. Closely comparable to Bora in scale, mammalian/microbial dual-platform offering, and end-to-end service model, though with broader geographic footprint.

TypeDirect peer
Description

U.S.-based CDMO specializing in mammalian and microbial biologics from clinical through commercial scale, including cell line development, process development, and GMP manufacturing. Most directly comparable mid-sized peer to Bora, with similar scale and mammalian/microbial dual-platform focus.

TypeEmerging player
Description

Clinical-stage biologics company developing antibody discovery and manufacturing capabilities for partners. Partial overlap with Bora's mammalian biologics development services, but with a stronger discovery-side focus and earlier-stage positioning in the value chain.

TypeBroad incumbent
Description

Large diversified CDMO with biologics drug substance and drug product capabilities, including fill-finish. Competes with Bora on mammalian biologics manufacturing and with affiliate Bora Pharmaceuticals on fill-finish; broader portfolio includes cell and gene therapy.

TypeBroad incumbent
Description

Biologics CDMO with mammalian and microbial development and manufacturing across sites in the U.S., U.K., and Japan. Competes with Bora for late-stage and commercial biologics programs, including biosimilars, with larger footprint and longer-tenured commercial supply relationships.

10Boehringer Ingelheim BioXcellence
TypeBroad incumbent
Description

Boehringer Ingelheim's biologics CDMO business offering mammalian cell culture and microbial contract manufacturing from clinical through commercial scale. A direct competitor in late-stage and commercial biologics CDMO, with similar end-to-end positioning but substantially larger scale.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bora Biologics

Biologics Contract Manufacturing (CDMO)borabiologics.com

Bora Biologics is a San Diego-based contract development and manufacturing organization (CDMO) specializing in mammalian and microbial biologics from cell line development through commercial GMP manufacturing and fill-finish services for biopharma sponsors.

What Bora Biologics does

Bora Biologics is a San Diego-headquartered contract development and manufacturing organization (CDMO) specializing in mammalian and microbial biologics, founded in 2011 as a subsidiary of Taiwan-based Tanvex BioPharma, Inc. The company provides end-to-end services spanning cell line development, upstream and downstream process development, analytical development, formulation development, GMP drug substance manufacturing, and tech transfer, with drug product fill-finish delivered through affiliate Bora Pharmaceuticals' 87,000 sf facility in Baltimore, MD. Its proprietary technology stack includes a CHO cell line platform achieving 4-6 g/L titers, an Allosteric Formulation Development Platform, and a Biophysical High Throughput Platform that uses advanced spectroscopic and biophysical instrumentation for rapid formulation screening. The company operates an FDA-registered facility in San Diego with newly validated 2,000L single-use bioreactor capacity (following a $30M expansion completed January 2026) and a TFDA-registered cGMP facility in Zhubei City, Taiwan, together totaling more than 175,000 sf of GMP and R&D space.

Bora Biologics employs 125 scientists and regulatory specialists (over 50% with advanced degrees) and has delivered 100+ cGMP batches across 50 biologic and biosimilar programs, including one commercial biosimilar approved in both the U.S. and Canada. Revenue is generated through project-based, fee-for-service CDMO contracts priced per engagement scope, typically structured as multi-year agreements with enterprise biopharma sponsors. The go-to-market model relies on direct enterprise sales, technical publications, case studies, and conference participation (BIO 2026, CDMO Live Europe), targeting mid-to-large biopharma and biotech sponsors needing late-stage and commercial-scale biologics manufacturing, particularly those seeking U.S.-based supply. Recent strategic activity — including the May 2026 acquisition of MacroGenics' GMP operations and the commercial-scale 2,000L validation — positions Bora as a scaling mid-market biologics CDMO with both clinical and commercial manufacturing capability across two regulatory jurisdictions.

Bora Biologics firmographics

Firmographics
Name
Bora Biologics
Legal name
Bora Biologics BioPharma, Inc.
Website
https://borabiologics.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Short description
Bora Biologics is a San Diego-based contract development and manufacturing organization (CDMO) specializing in mammalian and microbial biologics from cell line development through commercial GMP manufacturing and fill-finish services for biopharma sponsors.
Ownership category
akta.pro rank

Bora Biologics industry classification

Industry
Product category
Biologics Contract Manufacturing (CDMO)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Contract biologics manufacturing
  • Mammalian cell culture
  • Microbial fermentation
  • Biologics process development
  • Fill-finish services

Where Bora Biologics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Bora Biologics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing (CDMO) Services: Bora Biologics generates revenue through providing fee-for-service contract development and manufacturing services to biopharma sponsors. Services span the full product lifecycle from cell line development, process development, analytical development, GMP manufacturing (drug substance), through technology transfer. Revenue is project-based with custom scopes, timelines, and pricing negotiated per engagement. The company also transfers drug substances to its affiliate Bora Pharmaceuticals for fill-finish and drug product services, forming an integrated end-to-end CDMO offering.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom CDMO project pricing — scope-dependent, quote-based

Go-to-market motion1 record

Distribution channels1 record

Marketing channels9 records

Bora Biologics product offering

Product offering

Core offering

Bora Biologics is a contract development and manufacturing organization (CDMO) that provides end-to-end biologics services spanning cell line development, mammalian and microbial process development, analytical and formulation development, GMP drug substance manufacturing, and fill-finish drug product services. The company operates FDA-registered facilities in San Diego, CA and TFDA-registered facilities in Zhubei City, Taiwan, serving biopharma sponsors from preclinical through commercial-scale production of monoclonal antibodies, bispecifics, ADCs, fusion proteins, enzymes, and biosimilars.

Product overview

Bora Biologics is a technology-driven Contract Development and Manufacturing Organization (CDMO) offering an integrated platform spanning development through commercialization. The core offering consists of Mammalian GMP Manufacturing and Microbial GMP Manufacturing, complemented by development service modules including Cell Line Development, Mammalian Process Development, Microbial Process Development, Analytical Development, Formulation & Drug Product Development, and Tech Transfer. Drug Product Services (fill-finish) are delivered through partnership with Bora Pharmaceuticals. The company specializes in late-stage execution and commercial-scale production of biologics including monoclonal antibodies, bispecifics, ADCs, fusion proteins, and enzymes at FDA-registered facilities in San Diego, CA and Zhubei City, Taiwan.

Differentiator

Problem solved

Functional benefit

Products and services

  • Mammalian GMP Manufacturing Full-service mammalian cell culture manufacturing using single-use bioreactor technology (50L to 2,000L scale) with integrated upstream, downstream, and quality systems at the FDA-registered San Diego facility. Designed for biopharma sponsors requiring clinical-to-commercial scale GMP production.
  • Microbial GMP Manufacturing Efficient microbial-derived biologics manufacturing using stainless steel fermentors (150L, 300L) and single-use fermentation technology for secreted and intracellular products, serving sponsors from pre-clinical through commercial scale.
  • Drug Product Services Comprehensive fill-finish services including vials and pre-filled syringes, liquid and lyophilization, visual inspection, packaging, and serialization. Delivered through partnership with affiliate Bora Pharmaceuticals at the Baltimore, MD facility for clinical and commercial drug product manufacturing.
  • Cell Line Development Robust cell line development using a proprietary CHO cell line platform with CRISPR/Cas9 gene editing, clone screening, and characterization to create high-yield, stable cell lines for biologics production.
  • Mammalian Process Development Optimization of cell culture and downstream purification processes including high-throughput media screening, chromatography development, filtration process development, and scale-up to 2,000L batches for mammalian biologics production.
  • Microbial Process Development Scalable fermentation development for E. coli and yeast systems, including high-yield fermentation optimization, downstream purification, and process scale-up from pre-clinical to commercial scale.
  • Analytical Development Comprehensive analytical services including identity and purity testing, structural characterization, biological/functional characterization, microbiology testing, and analytical method validation for biologics.
  • Formulation & Drug Product Development Drug product formulation development using a proprietary Allosteric Formulation Development Platform and Biophysical HT Platform for rapid pre-formulation screening, stability assessment, and excipient compatibility studies.
  • Tech Transfer Technology transfer services ensuring smooth transition from development to manufacturing, including comprehensive assessment, cross-functional collaboration, and robust documentation practices; particularly used to transition Asia-based programs to U.S. commercial supply.

Quantifiable outcome

  • 40% increase in mammalian process yield through process development optimization
  • +4 more outcomes

Companies that use Bora Biologics

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Bora Biologics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Bora Biologics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Bora PharmaceuticalscoreStrategic or Co-development PartnerBora Biologics transfers biologic drug substances to its affiliate Bora Pharmaceuticals for comprehensive drug product (fill-finish) services. Bora Pharmaceuticals operates an 87,000 sf cGMP drug product facility in Baltimore, MD. This partnership enables an end-to-end CDMO offering from drug substance to drug product under an integrated 'Power of One' single-agreement model. The collaboration provides clinical and commercial manufacturing capabilities for vials, pre-filled syringes, liquid and lyophilized products, with inspection, packaging, and serialization.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Bora Biologics competitors and assessment

Company assessment

Broad incumbents

  • Thermo Fisher Scientific (Patheon / Brammer Bio): Through its pharma services segment, Thermo Fisher offers biologics CDMO capabilities including mammalian manufacturing and fill-finish. Competes with Bora across most service lines, with the advantage of integrated small-molecule, biologics, and clinical-trial-services capabilities.
  • Lonza Biologics: Global CDMO leader offering mammalian and microbial biologics development and manufacturing across multiple sites in Switzerland, the U.S., and Asia. Competes directly with Bora across the full biologics CDMO value chain, with far larger scale and longer commercial track record.
  • Samsung Biologics: One of the world's largest biologics CDMOs with 364,000L of total bioreactor capacity across multiple plants in Songdo, South Korea. Directly competes with Bora for late-stage and commercial mammalian biologics manufacturing, but at substantially larger scale and with broader capabilities.
  • WuXi Biologics: Major China-based biologics CDMO with extensive global capacity and integrated discovery-through-commercial services. Competes head-to-head with Bora for mammalian biologics programs, particularly sponsors with Asia-based clinical development seeking a CDMO partner.
  • Catalent (Novo Holdings): Large diversified CDMO with biologics drug substance and drug product capabilities, including fill-finish. Competes with Bora on mammalian biologics manufacturing and with affiliate Bora Pharmaceuticals on fill-finish; broader portfolio includes cell and gene therapy.
  • Fujifilm Diosynth Biotechnologies: Biologics CDMO with mammalian and microbial development and manufacturing across sites in the U.S., U.K., and Japan. Competes with Bora for late-stage and commercial biologics programs, including biosimilars, with larger footprint and longer-tenured commercial supply relationships.
  • Boehringer Ingelheim BioXcellence: Boehringer Ingelheim's biologics CDMO business offering mammalian cell culture and microbial contract manufacturing from clinical through commercial scale. A direct competitor in late-stage and commercial biologics CDMO, with similar end-to-end positioning but substantially larger scale.

Direct peers

  • AGC Biologics: Mid-to-large global CDMO offering mammalian and microbial biologics development and manufacturing from clinical through commercial scale. Closely comparable to Bora in scale, mammalian/microbial dual-platform offering, and end-to-end service model, though with broader geographic footprint.
  • Cytovance Biologics: U.S.-based CDMO specializing in mammalian and microbial biologics from clinical through commercial scale, including cell line development, process development, and GMP manufacturing. Most directly comparable mid-sized peer to Bora, with similar scale and mammalian/microbial dual-platform focus.

Emerging players

  • AbCellera Biologics: Clinical-stage biologics company developing antibody discovery and manufacturing capabilities for partners. Partial overlap with Bora's mammalian biologics development services, but with a stronger discovery-side focus and earlier-stage positioning in the value chain.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat6 records

Key highlights6 records

Customer concentration

Bora Biologics social profiles

Digital presence

Bora Biologics compliance and trust

Trust signal

Compliance4 records

Bora Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bora Biologics leadership team

Management profile

Number of profiles

Profiles8 records

Bora Biologics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bora Biologics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bora Biologics

What does Bora Biologics do?

Bora Biologics is a contract development and manufacturing organization (CDMO) that provides end-to-end biologics services spanning cell line development, mammalian and microbial process development, analytical and formulation development, GMP drug substance manufacturing, and fill-finish drug product services. The company operates FDA-registered facilities in San Diego, CA and TFDA-registered facilities in Zhubei City, Taiwan, serving biopharma sponsors from preclinical through commercial-scale production of monoclonal antibodies, bispecifics, ADCs, fusion proteins, enzymes, and biosimilars.

Is Bora Biologics a public or private company?

Bora Biologics is a private company. It is classified as corporate owned and is currently operating.

When was Bora Biologics founded?

Bora Biologics was founded in 2011. It employs 101 to 250 people.

Where is Bora Biologics based?

Bora Biologics is headquartered in San Diego, United States, in the North America region.

How does Bora Biologics make money?

One revenue line is on record: contract Development and Manufacturing (CDMO) Services.

Who are Bora Biologics's main competitors?

Broad incumbents on record are Thermo Fisher Scientific (Patheon / Brammer Bio), Lonza Biologics, Samsung Biologics, WuXi Biologics, Catalent (Novo Holdings), Fujifilm Diosynth Biotechnologies and Boehringer Ingelheim BioXcellence. Direct peers are AGC Biologics and Cytovance Biologics. AbCellera Biologics is listed as an emerging player.

Does Bora Biologics have an API?

No public API is recorded for Bora Biologics.

What industry is Bora Biologics in?

Bora Biologics's product category is Biologics Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAGAG, Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP). Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Laotian TimesTaiwan Biotech Delegation Showcases Regional Innovation in CDMO, Cell Therapy, and Biologics at BioJapan 2026Seventeen Taiwanese biotech companies and research institutions will showcase capabilities at BioJapan 2026 in Yokohama, Oct. 7-9. The delegation highlights CDMO, cell therapy, and biologics, including Bora Biologics' RAPClot supply deal and UnicoCell's Phase III enrollment. The 2025 Taiwan biotech sector generated NT$830.1 billion in revenue.FinanzNachrichten.deBora Biologics and Protect Animal Health Enter Strategic, Long-Term Multi-Project Collaboration to Advance Antibody-Based Animal Health ProductsBora Biologics and Protect Animal Health announced a long-term collaboration to develop and manufacture antibody-based animal health products. Protect expects to advance at least three programs, including two monoclonal and one bispecific antibody programs. The partnership marks Bora's first animal health collaboration and expands its platform into the sector.FinancialContent Business PageBora Biologics and Protect Animal Health Enter Strategic, Long-Term Multi-Project Collaboration to Advance Antibody-Based Animal Health ProductsBora Biologics and Protect Animal Health announced a long-term collaboration to develop and manufacture antibody-based veterinary products. Protect expects to advance at least three programs, including two monoclonal and one bispecific antibody programs. The partnership marks Bora's first animal health collaboration and expands its platform into the sector.NewswireBora Biologics Selected to Develop, Scale Up, and Supply RAPClot(TM) Protein Supporting Terumo's Japan Launch of RAPClot Blood Collection TubesBora Biologics entered a long-term supply agreement to provide recombinant RAPClot protein for Q Sera, supporting Terumo's Japan launch of VenoJect II RAPClot blood collection tubes. The agreement follows successful scale-up and marks the first commercial introduction of Q Sera's patented RAPClot technology.Genengnews10 CDMO Up & Comers 2026Ten CDMOs are listed as up-and-comers for 2026, including Artis BioSolutions, AsymBio, and Bora Group, with actions such as acquisitions, contracts, and facility openings. Bora Group completed a $127.5 million acquisition of MacroGenics and signed a $250 million GSK contract, while Resilience expanded its Eli Lilly partnership with a $750 million expansion.GlobalDataForeign CMOs expand US capacity as pharma supply chains regionalize, reveals GlobalData – GlobalDataForeign contract manufacturing organizations are expanding US capacity as pharma companies prioritize supply-chain resilience. Examples include Evonik's $100 million Indiana investment, Bora Biologics' $122.5 million acquisition, and Samsung Biologics' $280 million purchase of GSK's Maryland plant. The trend moves toward integrated, regionalized manufacturing to reduce geopolitical and tariff risks.FinancialContent Business PageBora Biologics Expands U.S. Commercial Manufacturing Platform with Addition of Rockville SiteBora Biologics announced the expansion of its U.S. drug substance manufacturing platform with the addition of a Rockville, Maryland site, bringing its total U.S. single-use bioreactor capacity to 20,000 liters across two FDA-registered facilities. The combined network includes seven 2,000L commercial bioreactors operating within a 100% single-use GMP architecture, with the Rockville site already actively manufacturing commercial product for six global markets. The company has executed over 200 GMP batches including more than 60 commercial batches with 100% first-pass PPQ success, supporting its positioning as a CDMO built for licensed commercial supply.MorningstarBora Biologics Expands U.S. Commercial Manufacturing Platform with Addition of Rockville SiteBora Biologics added a Rockville, Maryland site to its U.S. drug substance manufacturing platform, scaling single-use bioreactor capacity to 20,000 liters across two FDA-registered facilities. The company reports over 200 GMP batches, including 60 commercial batches, and supports six global markets.NewswireBora Biologics Expands U.S. Commercial Manufacturing Platform with Addition of Rockville SiteBora Biologics announced the expansion of its U.S. drug substance manufacturing platform through the addition of a Rockville, Maryland site, scaling total U.S. single-use bioreactor capacity to 20,000 liters across two FDA-registered facilities. The combined network now includes seven 2,000-liter commercial bioreactors operating within a 100% single-use GMP architecture, with over 60 commercial batches executed at 100% first-pass PPQ success. The company states the expansion positions it to capture late-stage programs as regulatory and policy environments increasingly prioritize secure domestic biologics manufacturing.PharmiWeb.comBora Biologics Successfully Completes 2,000L Engineering and Scale-Up Run in San Diego, Reinforcing Commercial-Scale ReadinessBora Biologics announced the successful completion of its first 2,000-liter engineering, scale-up, and process confirmation run at its FDA-approved San Diego facility, completing a $30 million expansion started in January 2026. The run validates operational readiness of expanded mammalian manufacturing suites, confirms the facility's integrated upstream, downstream, and quality systems at commercial scale, and includes scale-up of the TX05 trastuzumab biosimilar process from 1,000 to 2,000 liters. The company positions this capability to serve sponsors seeking U.S.-based late-stage and commercial biologics manufacturing, with recent global trade policy shifts increasing demand for domestic capacity.